You are here

  • Home
  • Archive
  • Volume 15, Issue 3
  • Nicotine patch plus lozenge gives greatest increases in abstinence from smoking rates at 6 months compared with placebo; smaller effects seen with nicotine patch alone, bupropion or nicotine lozenges alone or combined

Article Text

Article menu
Download PDFPDF
Therapeutics
Randomised controlled trial
Nicotine patch plus lozenge gives greatest increases in abstinence from smoking rates at 6 months compared with placebo; smaller effects seen with nicotine patch alone, bupropion or nicotine lozenges alone or combined

https://doi.org/10.1136/ebm1047

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests DG has received research contracts to study smoking cessation therapies from Pfizer, Nabi Biopharmaceuticals, Sanofi-Aventis and Addex Pharmaceuticals; consulting fees and honoraria for speaking to groups about smoking cessation from Pfizer; consulting fees for protocol development from Evotec Neurosciences; and reimbursements for travel expenses and meeting registrations for attending meetings relating to smoking cessation from Pfizer. DG owns five shares of Pfizer stock.